Cargando…

Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy

BACKGROUND: A predictive model for biochemical recurrence (BCR) of prostate cancer (PCa) after neoadjuvant androgen deprivation therapy (nADT) has not been established. This study was aimed at determining multiparameter variables that could be used to construct a nomogram to predict the post-nADT BC...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qi, Yang, Yuan-Zhong, Yang, Ping, Li, Yong-Hong, Cao, Yun, Chen, Dong, Zhang, Yijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406657/
https://www.ncbi.nlm.nih.gov/pubmed/37306931
http://dx.doi.org/10.1007/s11255-023-03658-2
_version_ 1785085791640223744
author Sun, Qi
Yang, Yuan-Zhong
Yang, Ping
Li, Yong-Hong
Cao, Yun
Chen, Dong
Zhang, Yijun
author_facet Sun, Qi
Yang, Yuan-Zhong
Yang, Ping
Li, Yong-Hong
Cao, Yun
Chen, Dong
Zhang, Yijun
author_sort Sun, Qi
collection PubMed
description BACKGROUND: A predictive model for biochemical recurrence (BCR) of prostate cancer (PCa) after neoadjuvant androgen deprivation therapy (nADT) has not been established. This study was aimed at determining multiparameter variables that could be used to construct a nomogram to predict the post-nADT BCR of PCa. METHODS: Overall, 43 radical prostatectomy specimens from PCa patients who had undergone nADT were collected. Multiparameter variables were analyzed by univariate and then multivariate logistic analyses to identify the independent prognostic factors for predicting BCR. The predictive model was established using Lasso regression analysis. RESULTS: Univariate logistic analysis revealed six variables, pathology stage; margins; categorization as group A, B, or C; nucleolus grading; percentage of tumor involvement (PTI); and PTEN status were significantly associated with the BCR of PCa (all p < 0.05). Multivariate logistic regression analysis suggested that categorization as group C, severe nucleolus grading, PTI less than or equal to 5%, and PTEN loss were positively correlated with BCR (all p < 0.05). A nomogram comprising the four variables predicting BCR was constructed, and it exhibited good discrimination (AUC: 0.985; specificity: 86.2%; sensitivity: 100%). Calibration plots for the probability of freedom from BCR at 1 and 2 years showed a good match between the prediction by the nomogram. CONCLUSIONS: We constructed and validated a nomogram to predict the risk of BCR in PCa patients after nADT. This nomogram is a complement to the existing risk stratification systems for PCa, which could have marked implications for clinical decision-making for PCa patients after nADT. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11255-023-03658-2.
format Online
Article
Text
id pubmed-10406657
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-104066572023-08-09 Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy Sun, Qi Yang, Yuan-Zhong Yang, Ping Li, Yong-Hong Cao, Yun Chen, Dong Zhang, Yijun Int Urol Nephrol Urology - Original Paper BACKGROUND: A predictive model for biochemical recurrence (BCR) of prostate cancer (PCa) after neoadjuvant androgen deprivation therapy (nADT) has not been established. This study was aimed at determining multiparameter variables that could be used to construct a nomogram to predict the post-nADT BCR of PCa. METHODS: Overall, 43 radical prostatectomy specimens from PCa patients who had undergone nADT were collected. Multiparameter variables were analyzed by univariate and then multivariate logistic analyses to identify the independent prognostic factors for predicting BCR. The predictive model was established using Lasso regression analysis. RESULTS: Univariate logistic analysis revealed six variables, pathology stage; margins; categorization as group A, B, or C; nucleolus grading; percentage of tumor involvement (PTI); and PTEN status were significantly associated with the BCR of PCa (all p < 0.05). Multivariate logistic regression analysis suggested that categorization as group C, severe nucleolus grading, PTI less than or equal to 5%, and PTEN loss were positively correlated with BCR (all p < 0.05). A nomogram comprising the four variables predicting BCR was constructed, and it exhibited good discrimination (AUC: 0.985; specificity: 86.2%; sensitivity: 100%). Calibration plots for the probability of freedom from BCR at 1 and 2 years showed a good match between the prediction by the nomogram. CONCLUSIONS: We constructed and validated a nomogram to predict the risk of BCR in PCa patients after nADT. This nomogram is a complement to the existing risk stratification systems for PCa, which could have marked implications for clinical decision-making for PCa patients after nADT. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11255-023-03658-2. Springer Netherlands 2023-06-12 2023 /pmc/articles/PMC10406657/ /pubmed/37306931 http://dx.doi.org/10.1007/s11255-023-03658-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Urology - Original Paper
Sun, Qi
Yang, Yuan-Zhong
Yang, Ping
Li, Yong-Hong
Cao, Yun
Chen, Dong
Zhang, Yijun
Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
title Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
title_full Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
title_fullStr Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
title_full_unstemmed Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
title_short Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
title_sort nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
topic Urology - Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406657/
https://www.ncbi.nlm.nih.gov/pubmed/37306931
http://dx.doi.org/10.1007/s11255-023-03658-2
work_keys_str_mv AT sunqi nomogramforpredictingthebiochemicalrecurrenceofprostatecancerafterneoadjuvantandrogendeprivationtherapy
AT yangyuanzhong nomogramforpredictingthebiochemicalrecurrenceofprostatecancerafterneoadjuvantandrogendeprivationtherapy
AT yangping nomogramforpredictingthebiochemicalrecurrenceofprostatecancerafterneoadjuvantandrogendeprivationtherapy
AT liyonghong nomogramforpredictingthebiochemicalrecurrenceofprostatecancerafterneoadjuvantandrogendeprivationtherapy
AT caoyun nomogramforpredictingthebiochemicalrecurrenceofprostatecancerafterneoadjuvantandrogendeprivationtherapy
AT chendong nomogramforpredictingthebiochemicalrecurrenceofprostatecancerafterneoadjuvantandrogendeprivationtherapy
AT zhangyijun nomogramforpredictingthebiochemicalrecurrenceofprostatecancerafterneoadjuvantandrogendeprivationtherapy